ArticleTherapeutic advances in medical oncology2020
Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial.
Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01878422 (SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sequential treatment strategy for metastatic colorectal cancer: a phase iii prospective randomized multicenter study of chemotherapy (ct) with or without bevacizumab as first-line therapy followed by two phase iii randomized studies of ct alone or ct plus bevacizumab with or without cetuximab as second-line therapy
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prognostic value of systemic immune-inflammation index for colorectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value and clinicopathological significance of pre-and post-treatment systemic immune-inflammation index in colorectal cancer patients: a meta-analysis.World journal of surgical oncology · 2025Pooled it
- A clinical study on the application of new inflammatory markers SII, SIRI, AISI, and MII in the identification of severe acute pancreatitis.Frontiers in medicine · 2026Article
- Evaluation of multi-inflammatory ındexes in persons living with human immunodeficiency virus: a multicenter study.Revista da Associacao Medica Brasileira (1992) · 2026Observational
- Multi-Inflamatuar Index is a New Predictive Parameter for Early-Term Mortality in Patients Undergoing Endovascular Aortic Repair for Ruptured Abdominal Aortic Aneurysm.The Eurasian journal of medicine · 2025Article
- Effect of Machine Learning on Risk Stratification for Antiretroviral Treatment Failure in People Living with HIV.Infection and drug resistance · 2025Article
- The association between multi-inflammatory index and long-term mortality in post-myocardial infarction patients treated with percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2025Article
- Predictive value of inflammatory markers (NLR, PLR, MLR, SII, SIRI, PIV, IG, and MII) for latency period in Preterm premature rupture of membranes (PPROM) pregnancies.BMC pregnancy and childbirth · 2024Article
- Prognostic value of sarcopenia and inflammatory indices synergy in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy.BMC cancer · 2024Article
- Comparison of Inflammatory Marker Scoring Systems and Conventional Inflammatory Markers in Patients over 65 Years of Age Admitted to the Intensive Care Unit: A Multicenter, Retrospective, Cohort Study.Journal of clinical medicine · 2024Article
- Application of Multi-Inflammatory Index to Predict Atrial Fibrillation Risk in Patients with Coronary Heart Disease: A Retrospective Machine Learning Study.Risk management and healthcare policy · 2024Article
- The Role of the Multi-Inflammatory Index as a Novel Predictor of Hospital Mortality in Acute Ischemic Stroke.Cureus · 2023Article
- Serial Changes in Blood-Cell-Count-Derived and CRP-Derived Inflammatory Indices of COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2023Article
- Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.Therapeutic advances in medical oncology · 2023Article
- Predictive value of prognostic nutritional and systemic immune-inflammation indices for patients with microsatellite instability-high metastatic colorectal cancer receiving immunotherapy.Frontiers in nutrition · 2023Article
- Multi-inflammatory Index as a Novel Mortality Predictor in Critically Ill COVID-19 Patients.Journal of intensive care medicine · 2022Article
- The combination of fibrinogen concentrations and the platelet-to-lymphocyte ratio predicts survival in patients with advanced lung adenocarcinoma treated with EGFR-TKIs.The Journal of international medical research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe created a new index (Multi Inflammatory Index, MII) composed of an inflammatory index [neutrophil-to lymphocyte-ratio (NLR): MII-1; platelet-to-lymphocyte ratio (PLR): MII-2; or systemic immune-inflammation index (SII): MII-3] and C-reactive protein (CRP). Our aim was to evaluate the prognostic and/or predictive capacity of the MII in the randomized ITACa (Italian Trial in Advanced Colorectal Cancer) study on patients with metastatic colorectal cancer undergoing first-line chemotherapy.
methodsBetween November 2007 and March 2012, baseline NLR, PLR; SII and CRP were available for 131 patients, 66 receiving chemotherapy plus bevacizumab and 65 receiving chemotherapy alone.
resultsPatients with low (<25) MII-1 levels had a better outcome than those with high (⩾25) levels: median progression-free survival (PFS) was 12.4
conclusionAll MII indexes appear to be useful as prognostic markers.
trial registrationClinicalTrials.gov identifier: NCT01878422 (registration date: 07/06/2013) https://clinicaltrials.gov/ct2/show/NCT01878422.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.